Shots:
- Bio-Thera and Avalon Pharma have signed commercialization and licensing agreements for BAT3306, a biosimilar version of Keytruda (Pembrolizumab)
- As per the deal, Bio-Thera will oversee development, manufacturing, and supply of BAT3306, while Avalon Pharma will handle regulatory approvals and commercialization across Saudi Arabia and the MENA region
- BAT3306 is a humanized monoclonal antibody and immune checkpoint inhibitor for cancer immunotherapy. Like pembrolizumab, it blocks the PD-1 receptor on T cells, preventing its interaction with PD-L1 and PD-L2 to enhance anti-tumor immune response
Ref: Bio-Thera | Image: Bio-Thera and Avalon Pharma | Press Release
Related News: STADA & Bio-Thera Receive the CHMP Positive Opinion for Gotenfia (Biosimilar, Simponi)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
